with the plunge in sales revenue. Nevertheless, some of the sales expenses did not adjust promptly and did not fully mirror the slowdown in revenue as there is a lead time for certain expenses that the

granted a license from China Food and Drug Administration (CFDA) during the beginning of 2018 as the Company had to redesign and adjust product packaging according to the granted license as well as change

issued from China Food and Drug Administration (CFDA) at the beginning of 2018 as the Company had to redesign its packaging to comply with the requirements of the license and adjust its sales structures

that the Company managed to properly slash sales expenses from the previous year to be in parallel with the plunge in sales revenue. Nevertheless, some of the sales expenses did not adjust promptly and

a Private Visit to facilitate those who need to visit the project. In this regard, the Company will closely monitor the situation of COVID-19 and continuously adjust the operation pattern to keep up

benefit expenses For Quarter 2 of the year 2020, the management benefit was 3.24 million baht compare to 3.77 million baht, decrease by 0.53 million or 14.06% decreased because the company had adjust the

the Connected Transaction Regarding the Offering of Newly Issued Ordinary Shares to the Specific Investors (Private Placement), i.e. Silom Road Limited and Mr. Viroj Tangjettanaporn The Board of

“Terms and Conditions of MACO-W2”), the condition of the adjustment of rights under the MACO-W2 states that the Company shall adjust the exercise price and/or the exercise ratio to purchase the Company’s

shares of KPN Academy Company Limited (“KPN Academy”) in the proportion of not less than 57.52 percent of total number of sold shares of KPN Academy from the existing shareholders, i.e. (1) Mr. Nop

Academy Company Limited (“KPN Academy”) in the proportion of not less than 57.52 percent of total number of sold shares of KPN Academy from the existing shareholders, i.e. (1) Mr. Nop Narongdej (2) Golden